Stereotaxis Inc. today announced that its Genesis Robotic Magnetic Navigation system has been used successfully to treat patients at Fred & Lena Meijer Heart Center in Grand Rapids, Mich.
Electrophysiologists at Corewell Health, which the Heart Center is a part of, have established a successful robotic cardiac ablation program, treating nearly 500 patients using advanced robotic technology. The hospital is now among the first in the world, and the first in Michigan, to offer the latest in RMN technology with the Genesis system, according to Saint Louis-based Sterotaxis.
“Robotics is an integral part of our electrophysiology program at Corewell Health and reflects our ongoing commitment of being at the forefront of cardiovascular care,” said Dr. Musa Dahu, cardiac electrophysiologist at Corewell Health. “Adopting the Genesis RMN system will allow us to continue to provide the most advanced care for patients including those suffering from the most complex cardiac arrhythmias.”
Stereotaxis said it is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention.
Its mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory.
These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room, the company said. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere
RMN brings robotic precision to heart surgery
Robotic Magnetic Navigation was introduced to bring the benefits of robotic precision to cardiac ablation, a common minimally invasive procedure to treat arrhythmias, the company said.
Tens of millions of individuals worldwide suffer from arrhythmias—abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, arrhythmias may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest, the company added.
“We are delighted to continue our partnership with the physicians at Corewell Health as they advance the frontiers of patient care and clinical science,” said David Fischel, Chairman and CEO of Stereotaxis. “We look forward to working with Corewell Health to extend its leadership in arrhythmia care in Grand Rapids.”